Abstract
In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.
Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI
Infectious Disorders - Drug Targets
Title: In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)
Volume: 6 Issue: 3
Author(s): Martin Handfield and Jeffrey D. Hillman
Affiliation:
Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI
Abstract: In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.
Export Options
About this article
Cite this article as:
Handfield Martin and Hillman D. Jeffrey, In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT), Infectious Disorders - Drug Targets 2006; 6 (3) . https://dx.doi.org/10.2174/187152606778249908
DOI https://dx.doi.org/10.2174/187152606778249908 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF as a Target of Inflammation in Rheumatoid Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers
Current Medicinal Chemistry Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Withdrawal Notice: EnzyPha, an Engineered Helper Phage Developed to Overcome Most of the Limitations Regarding Filamentous Phage Titration and ELISA Tests
Protein & Peptide Letters Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Neuroimmunomodulation and Aging: A Role for Transferrin and the Hypothalamus/Thymus Axis
Current Aging Science Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) A Novel Support Vector Machine Classifier Using Soft Computing Approach for Automated Classification of Emphysema, Bronchiectasis and Pleural Effusion Using Optimized Gabor Filter
Current Signal Transduction Therapy Emergence in Pyrazolines: Synthetic and Biological Perspective
The Natural Products Journal Preface [Hot Topic: Antimycobacterial Drugs: Current Status and Future Prospects (Executive Editor: Haruaki Tomioka)]
Current Pharmaceutical Design Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Enoyl ACP Reductase as Effective Target for the Synthesized Novel Antitubercular Drugs: A-State-of-the-Art
Mini-Reviews in Medicinal Chemistry Lactoferricin Derived From Milk Protein Lactoferrin
Current Pharmaceutical Design